H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AQST stock, giving a Buy rating on March 6.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to both current performance and future growth potential. While Aquestive’s latest results slightly trailed his revenue and earnings expectations because of higher operating costs, his forward outlook reflects confidence, as he modestly trimmed 2026 sales estimates and introduced a significantly higher 2027 revenue forecast that assumes accelerating momentum.
He places particular emphasis on the late-stage pipeline, especially Anaphylm, which he believes is still on track for eventual U.S. approval despite the prior FDA Complete Response Letter focused on human‑factors issues rather than efficacy, safety, or manufacturing concerns. With remedial design changes, a new validation study, and a clear regulatory plan toward resubmission and a potential 2027 launch, he views Anaphylm as a major value driver and therefore reiterates a Buy rating and a $10 twelve‑month price target.
In another report released on March 6, Leerink Partners also reiterated a Buy rating on the stock with a $9.00 price target.